Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04585477
Title Adjuvant Durvalumab for Early Stage NSCLC Patients With ctDNA Minimal Residual Disease
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Stanford University
Indications

lung non-small cell carcinoma

Therapies

Durvalumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST